Previous 10 | Next 10 |
Look at the comments on past Alnylam ( ALNY ) articles, and you'll see a vocal cadre of readers who have an otherwise admirable commitment to the notion that Alnylam is going to stumble at some point and not get up … and yet, the company keeps on executing past those worries. While th...
Alnylam Pharmaceuticals, Inc (ALNY) Q2 2020 Results Conference Call August 06, 2020 08:30 AM ET Company Participants Christine Lindenboom - Senior Vice President of Investor Relations John Maraganore - Chief Executive Officer Barry Greene - President Akshay Vaishnaw - Presiden...
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...
After 17 years, Barry Greene, president of Alnylam Pharmaceuticals (NASDAQ: ALNY ) decided to leave at the end of Q3 to pursue outside interests in the bio-pharmaceutical industry. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) : Q2 Non-GAAP EPS of -$1.67; GAAP EPS of -$1.56 beats by $0.23 . More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
− Achieved Second Quarter 2020 ONPATTRO ® Global Net Product Revenues of $66.5 Million, with More Than 1,050 Patients on Commercial Product Worldwide – − Achieved Second Quarter 2020 GIVLAARI® Global Net Product Revenues of $11.0 Million with More Than 1...
- Greene to Pursue New Opportunities at End-Q3, While Remaining a Consultant for Up to Two Years to Ensure Orderly Transition - - Yvonne Greenstreet to be Named President and Chief Operating Officer; Company Initiates Search for a Chief Commercial Officer - Alnylam Pharmaceutical...
– Company Expects to Initiate a Phase 1 Study in Late 2020 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthc...
Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2020 on Thursday, August 6, 2020, before the U.S. financial markets open. Management will provide an update o...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...